Background: Self-report is the most common and feasible method for assessing patient adherence to medication, but can be prone to recall bias and social desirability bias. Most studies assessing adherence to artemisinin-based combination therapies (ACTs) have relied on self-report. In this study, we use a novel customised electronic monitoring device--termed smart blister packs--to examine the validity of self-reported adherence to artemether-lumefantrine (AL) in southern Tanzania.
Methods: Smart blister packs were designed to look identical to locally available AL blister packs and to record the date and time each tablet was removed from packaging. Patients obtaining AL at randomly selected health facilities and drug stores were followed up at home three days later and interviewed about each dose of AL taken. Blister packs were requested for pill count and extraction of smart blister pack data.
Results: Data on adherence from both self-report verified by pill count and smart blister packs were available for 696 of 1,204 patients. There was no difference between methods in the proportion of patients assessed to have completed treatment (64% and 67%, respectively). However, the percentage taking the correct number of pills for each dose at the correct times (timely completion) was higher by self-report than smart blister packs (37% vs. 24%; p<0.0001). By smart blister packs, 64% of patients completing treatment did not take the correct number of pills per dose or did not take each dose at the correct time interval.
Conclusion: Smart blister packs resulted in lower estimates of timely completion of AL and may be less prone to recall and social desirability bias. They may be useful when data on patterns of adherence are desirable to evaluate treatment outcomes. Improved methods of collecting self-reported data are needed to minimise bias and maximise comparability between studies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516331 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0134275 | PLOS |
Cureus
September 2024
Internal Medicine, Max Smart Super Speciality Hospital, Saket, New Delhi, IND.
ACS Appl Mater Interfaces
April 2024
Key Laboratory of Eco-textiles of Ministry of Education, Jiangnan University, Wuxi 214122, China.
Smart wearables with the capability for continuous monitoring, perceiving, and understanding human tactile and motion signals, while ensuring comfort, are highly sought after for intelligent healthcare and smart life systems. However, concurrently achieving high-performance tactile sensing, long-lasting wearing comfort, and industrialized fabrication by a low-cost strategy remains a great challenge. This is primarily due to critical research gaps in novel textile structure design for seamless integration with sensing elements.
View Article and Find Full Text PDFSensors (Basel)
July 2023
Research Center for Agricultural Robotics, Core Technology Research Headquarters, NARO, Tsukuba 305-0856, Japan.
Nat Commun
July 2023
Department of Molecular Biology and Biochemistry, Rutgers University, Piscataway, NJ, 08855, USA.
Toxic protein aggregates can spread among neurons to promote human neurodegenerative disease pathology. We found that in C. elegans touch neurons intermediate filament proteins IFD-1 and IFD-2 associate with aggresome-like organelles and are required cell-autonomously for efficient production of neuronal exophers, giant vesicles that can carry aggregates away from the neuron of origin.
View Article and Find Full Text PDFInt J Mol Sci
February 2023
EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.
Mutations in the gene lead to malfunction, reduction or complete absence of type VII collagen (C7) in the skin's basement membrane zone (BMZ), impairing skin integrity. In epidermolysis bullosa (EB), more than 800 mutations in have been reported, leading to the dystrophic form of EB (DEB), a severe and rare skin blistering disease associated with a high risk of developing an aggressive form of squamous cell carcinoma. Here, we leveraged a previously described 3'-RTMS6m repair molecule to develop a non-viral, non-invasive and efficient RNA therapy to correct mutations within via spliceosome-mediated RNA -splicing (SMaRT).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!